DEANNA EDWARDS: Open Payments
NPI 1851406912 · OMAHA, NE. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$222 in 13 payments from 10 companies in 2025. Trend: 2023 $440 · 2024 $446 · 2025 $222
Food & beverage: $222
| Company | Payments | Amount |
|---|---|---|
| PFIZER INC. | 3 | $61 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | 2 | $40 |
| Sumitomo Pharma America, Inc. | 1 | $20 |
| Boston Scientific Corporation | 1 | $19 |
| Ascensia Diabetes Care Us Inc. | 1 | $16 |
| Otsuka America Pharmaceutical, Inc. | 1 | $16 |
| Xeris Pharmaceuticals, Inc. | 1 | $15 |
| AstraZeneca Pharmaceuticals LP | 1 | $14 |
| Lilly USA, LLC | 1 | $14 |
| Phathom Pharmaceuticals, Inc. | 1 | $7 |
Products named: JARDIANCE, PAXLOVID, GEMTESA, WATCHMAN FLX, VYNDAMAX, REXULTI, KEVEYIS, MOUNJARO.
Industry payments across NE — which companies pay providers there.
